Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by t…
This bill (Women’s Health and Cancer Rights Modernization Act of 2025) amends the Public Health Service Act, ERISA, and the Internal Revenue Code to require group health plans and health insurance issuers to cover specified items and services related to breast or chest wall reconstruction when furnished in connection with breast cancer treatment. It enumerates covered reconstruction modalities and types (including implant- and tissue-based approaches, future modalities incorporated in HCPCS Level I, and procedural variations), all stages of reconstruction (including flat closure), contralateral symmetry surgery, custom prostheses, and treatment of physical complications such as lymphedema.
Scope and affordability: progressives emphasize low or no out-of-pocket costs and stronger access standards, conservatives emphasize avoiding new federal mandate costs.
Relative to its intended legislative type, this bill is a clearly structured statutory coverage mandate that integrates changes across PHSA, ERISA, and the IRC and specifies a comprehensive set of covered reconstruction services and associated procedural requirements.
This bill (Women’s Health and Cancer Rights Modernization Act of 2025) amends the Public Health Service Act, ERISA, and the Internal Revenue Code to require group health plans and health insurance issuers to cover specified items and services related to breast or chest wall reconstruction when furnished in connection with breast cancer treatment.
It enumerates covered reconstruction modalities and types (including implant- and tissue-based approaches, future modalities incorporated in HCPCS Level I, and procedural variations), all stages of reconstruction (including flat closure), contralateral symmetry surgery, custom prostheses, and treatment of physical complications such as lymphedema.
The bill requires plans to provide coverage in consultation with the attending physician and patient, permit cost-sharing consistent with other plan benefits, require at least one in-network provider for each modality/type, mandate written notice to enrollees, and prohibit insurers or plans from denying enrollment or penalizing providers to avoid these requirements.
On content alone, the bill modernizes and clarifies existing coverage obligations in a narrowly tailored way and addresses a low-salience, broadly sympathetic medical need—factors that tend to increase odds of enactment. However, it imposes new coverage and network requirements on private plans (raising insurer/employer cost concerns), amends multiple statutes (which can complicate markup and intercommittee negotiations), and faces the ordinary legislative barriers in the Senate. Without a cost estimate, stakeholder buy-in, or a clear legislative vehicle, the measure has a modest-to-fair chance of becoming law based solely on its content.
Relative to its intended legislative type, this bill is a clearly structured statutory coverage mandate that integrates changes across PHSA, ERISA, and the IRC and specifies a comprehensive set of covered reconstruction services and associated procedural requirements. It includes a GAO report requirement as a secondary reporting element.
Scope and affordability: progressives emphasize low or no out-of-pocket costs and stronger access standards, conservatives emphasize avoiding new federal mandate costs.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and affordability: progressives emphasize low or no out-of-pocket costs and stronger access standards, conservatives emphasize avoiding new federal mandate costs.
A mainstream liberal/left-leaning observer would likely view the bill positively as an important expansion and modernization of protections ensuring that people undergoing breast cancer treatment have access to a full range of reconstruction options and related care.
The explicit inclusion of multiple modalities, future modalities recognized by HCPCS Level I, flat closure, prostheses replacement, and lymphedema treatment would be seen as filling coverage gaps and protecting patient choice.
They would welcome notice and anti-penalty provisions but may want stronger limits on cost-sharing and clearer requirements to ensure timely access to specialists, particularly for marginalized or rural patients.
A centrist/moderate observer would likely view the bill as a narrowly targeted, pragmatic update to existing law that clarifies and modernizes coverage obligations for reconstruction after breast cancer treatment.
They would appreciate that the bill keeps cost-sharing consistent with existing plan rules, allows reimbursement negotiation, and includes anti-avoidance and notice provisions; they would also want more information about likely costs and administrative impacts.
They would probably support the bill overall while seeking modest technical adjustments or implementation guidance to limit unintended burdens on employers and insurers and to ensure provider access is meaningful.
A mainstream conservative observer would likely be cautious or somewhat skeptical about this bill.
While they may sympathize with ensuring access to reconstruction for breast cancer patients (a policy with bipartisan precedent), they would be concerned about additional federal mandates on private plans, possible premium or employer cost increases, and expansions of federal regulatory reach into employer-sponsored plans.
They would also watch for burdens on small employers, potential increases in healthcare utilization or litigation over coverage scope, and unclear fiscal consequences.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill modernizes and clarifies existing coverage obligations in a narrowly tailored way and addresses a low-salience, broadly sympathetic medical need—factors that tend to increase odds of enactment. However, it imposes new coverage and network requirements on private plans (raising insurer/employer cost concerns), amends multiple statutes (which can complicate markup and intercommittee negotiations), and faces the ordinary legislative barriers in the Senate. Without a cost estimate, stakeholder buy-in, or a clear legislative vehicle, the measure has a modest-to-fair chance of becoming law based solely on its content.
The bill has not accumulated any surfaced votes yet.
Scope and affordability: progressives emphasize low or no out-of-pocket costs and stronger access standards, conservatives emphasize avoidi…
On content alone, the bill modernizes and clarifies existing coverage obligations in a narrowly tailored way and addresses a low-salience,…
Relative to its intended legislative type, this bill is a clearly structured statutory coverage mandate that integrates changes across PHSA, ERISA, and the IRC and specifies a comprehensive set of covered reconstruction…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.